DC Chemicals Limited
China
Product Name: Pyrazoloacridine
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

99009-20-8

99009-20-8 structure

Name: Pyrazoloacridine
Chemical Name: 3-(9-Methoxy-5-nitropyrazolo[3,4,5-kl]acridin-2(1H)-yl)-N,N-dimet hyl-1-propanamine
CAS Number: 99009-20-8
Molecular Formula: C₁₉H₂₁N₅O₃
Molecular Weight: 367.40200
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2017-09-15 21:24:18
Modify Date: 2024-01-11 19:33:37
Pyrazoloacridine (NSC 366140), an intercalating agent with anti-cancer activity, inhibits the activity of topoisomerases 1 and 2. Pyrazoloacridine (NSC 366140) exhibits an IC50 of 1.25 μM in K562 myeloid leukemia cells for 24 h treatment[1][2].

Name	3-(9-Methoxy-5-nitropyrazolo[3,4,5-kl]acridin-2(1H)-yl)-N,N-dimet hyl-1-propanamine
Synonyms	Fluoren-9-yl-methyl-aether 9-Methoxy-fluoren 9-methoxyfluorene fluoren-9-yl-methyl ether 9-Methoxyellipticine 9-methoxy-9H-fluorene methoxyellipticine

Description	Pyrazoloacridine (NSC 366140), an intercalating agent with anti-cancer activity, inhibits the activity of topoisomerases 1 and 2. Pyrazoloacridine (NSC 366140) exhibits an IC50 of 1.25 μM in K562 myeloid leukemia cells for 24 h treatment[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase
In Vitro	Pyrazoloacridine (NSC 366140, PD 115934) exhibits IC50 values of 10.7 μM and 4.5 μM for oxic and hypoxic HCT-8 cells[1]. Pyrazoloacridine (NSC 366140, 2-4 μM) abolishes the catalytic activity of both topo I and topo II in vitro[2]. Pyrazoloacridine (NSC 366140) displays activity against cisplatin- and paclitaxel-resistant ovarian cancer[2]. Pyrazoloacridine (NSC 366140) has been shown to cause delayed DNA fragmentation in MCF-7 breast cancer cells[2]. Pyrazoloacridine (NSC 366140) induces apoptosis in P53-deficient Hep 3B human hepatoma cells[2]. Cell Cytotoxicity Assay[2] Cell Line: K562 Myeloid Leukemia Cells. Concentration: 0-500 μM. Incubation Time: 1 h or 24 h. Result: When K562 cells were incubated with PA for 1 h and then plated in soft agar, an IC50 of -50 μM was observed. In contrast, when cells were incubated for 24 h with PA, the IC50 was 1.25 μM.
References	[1]. J S Sebolt, et al. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res. 1987 Aug 15;47(16):4299-304. [2]. A A Adjei, et al. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res. 1998 Mar;4(3):683-91.

Density	1.314g/cm3
Boiling Point	595.6ºC at 760 mmHg
Molecular Formula	C₁₉H₂₁N₅O₃
Molecular Weight	367.40200
Flash Point	314ºC
Exact Mass	367.16400
PSA	91.90000
LogP	4.06250
Index of Refraction	1.678

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UQ9826800

CHEMICAL NAME :: Pyrazolo(3,4,5-kl)acridine-2(6H)-propanamine, N,N-dimethyl-9-methoxy-5-nitro-

CAS REGISTRY NUMBER :: 99009-20-8

LAST UPDATED :: 199612

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: C19-H21-N5-O3

MOLECULAR WEIGHT :: 367.45

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

TYPE OF TEST :: Mutation test systems - not otherwise specified

TEST SYSTEM :: Rodent - mouse Leukocyte

DOSE/DURATION :: 1320 nmol/L

REFERENCE :: CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 47,4299,1987

55775-97-8

99009-20-8

Literature: Capps, David B.; Dunbar, James; Kesten, Suzanne R.; Shillis, Joan; Werbel, Leslie M.; et al. Journal of Medicinal Chemistry, 1992 , vol. 35, # 26 p. 4770 - 4778

55776-09-5

99009-20-8

Literature: Capps, David B.; Dunbar, James; Kesten, Suzanne R.; Shillis, Joan; Werbel, Leslie M.; et al. Journal of Medicinal Chemistry, 1992 , vol. 35, # 26 p. 4770 - 4778

104-94-9

99009-20-8

Literature: Capps, David B.; Dunbar, James; Kesten, Suzanne R.; Shillis, Joan; Werbel, Leslie M.; et al. Journal of Medicinal Chemistry, 1992 , vol. 35, # 26 p. 4770 - 4778